Related Experiment Video
Updated: May 11, 2026
03:37
Intravitreal Injections in the Ovine Eye
Published on: July 5, 2022
Intravitreal anti-VEGF therapy for retinal macroaneurysm
S A Zweifel1, M S Tönz, L Pfenninger
1University Hospital Zurich, Department of Ophthalmology, Zurich, Switzerland. sandrine.zweifel@gmail.com
Klinische Monatsblatter Fur Augenheilkunde
|May 1, 2013
Summary
Intravitreal anti-vascular endothelial growth factor (VEGF) therapy with bevacizumab or ranibizumab effectively treated retinal macroaneurysms and macular exudation, improving visual acuity and reducing retinal thickness.
Area of Science:
- Ophthalmology
- Medical Retina
- Vascular Diseases
Background:
- Retinal macroaneurysms with macular exudation pose a significant challenge in ophthalmology.
- Current treatment options may have limitations, necessitating evaluation of alternative therapies.
Purpose of the Study:
- To evaluate the efficacy of intravitreal anti-vascular endothelial growth factor (VEGF) therapy using bevacizumab or ranibizumab for retinal macroaneurysms with macular exudation.
Main Methods:
- A retrospective interventional case series was conducted.
- Patients received either intravitreal bevacizumab (1.25 mg) or ranibizumab (0.5 mg) as first-line therapy.
- Fluorescein angiography and optical coherence tomography were used for imaging, with retreatment for persistent fluid.
Main Results:
- Ten patients with macular macroaneurysms received an average of 3.0 anti-VEGF injections.
- Mean best-corrected visual acuity improved by 17 letters.
- Marked regression of macular exudation was observed in 80% of patients, with decreased central retinal thickness in those with foveal involvement.
Conclusions:
- Intravitreal anti-VEGF therapy is a promising alternative to laser treatment for retinal macroaneurysms with macular exudation.
- This treatment approach demonstrated significant visual and anatomical improvements.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...